Vistim Labs

Vistim Labs develops Ceregram, a patented Evoked Potential Tomography (EPT) technology for non-invasive, radiation-free neurological monitoring. The platform is designed to track disease progression in dementia patients (Alzheimer's, Parkinson's, Lewy Body Disease) and other neurological disorders by localizing and quantifying sensory deficits caused by neurodegeneration. Ceregram monitors across multiple disease endpoints including brain volume changes, physiological markers (amyloid and tau accumulation), and psychological/cognitive performance metrics (MMSE, CERAD, TASIT). The technology enables point-of-care evaluation in office-based clinical settings, allowing physicians to assess treatment response and adjust disease management in real time without requiring PET imaging or other advanced neuroimaging. The company has published peer-reviewed research in Alzheimer's Research and Therapy Journal and presented findings at major conferences including the American Academy of Neurology (2025) and Alzheimer's Association International Conference (2023). Ceregram is positioned as a clinical decision-support tool for cognitive monitoring and is not intended as a diagnostic device or replacement for PET, MRI, or other imaging modalities. The company operates with offices in Miami and San Diego, with affiliate locations in New York, Paris, and Berlin. Vistim Labs has participated in biotech accelerators (PharmStars, Boston) and won multiple startup pitch competitions.